Loading clinical trials...

Alipogene Tiparvovec for the Treatment of LPLD Patients | Clinical Trials | Clareo Health

WITHDRAWNPhase 2NCT02904772

Alipogene Tiparvovec for the Treatment of LPLD Patients

The aim of the study is to provide further confirmatory evidence of clinical benefit in LPLD patients treated with alipogene tiparvovec by assessing both the "clinical response" (as defined by a range...

Lead sponsor: UniQure Biopharma B.V.•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Trial snapshot

StatusWITHDRAWN

PhasePHASE2

Enrollment—

Start dateOct 2016

Last updatedAug 17, 2017

Condition

LPL Deficiency

Locations shown

Perelman School of Medicine at The University of Pennsylvania Translational Medicine & Human Genetics

Philadelphia, Pennsylvania

Centre hospitalier universitaire de Sherbrooke

Sherbrooke, Quebec

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 17, 2017Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions